Co-Diagnostics, Inc. (CODX) News
Filter CODX News Items
CODX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CODX News Highlights
- CODX's 30 day story count now stands at 8.
- Over the past 14 days, the trend for CODX's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about CODX are BIIB, MED and STAR.
Latest CODX News From Around the Web
Below are the latest news stories about Co-Diagnostics Inc that investors may wish to consider to help them evaluate CODX as an investment opportunity.
Co-Diagnostics, Inc. to Sponsor and Present at Molecular Med Tri-Con 2022Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be a premium sponsor of the upcoming Molecular Med Tri-Con held February 21-23, 2022 in San Diego, CA, which will also include a presentation by representatives of the Company and its newly-acquired subsidiary. |
Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State CapitalCo-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building. |
Wall Street Analysts Are Bullish on Top Healthcare PicksThere's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Co-Diagnostics (CODX – Research Report), Tempest Therapeutics (TPST – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments. Co-Diagnostics (CODX) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Co-Diagnostics, with a price target of $15.00. The company's shares closed last Thursday at $6.83, close to its 52-week low of $6.48. According to TipRanks.com, Chen is a 5-star analyst with an average return of -18.8% and a 23.8% success rate. |
Co-Diagnostics announces approval for Hep B test in IndiaCo-Diagnostics (NASDAQ:CODX) announced its joint venture in India, CoSara Diagnostics, received clearance from the regulatory authorities to manufacture and sell SARAQ Hepatitis B (HBV) Viral Load Kit there as an in vitro diagnostic ("IVD"). The real-time PCR test for HBV is based on Co-Diagnostics’ (CODX) CoPrimer technology, and it will... |
Co-Diagnostics announces approval for Hep B test in India (NASDAQ:CODX)Co-Diagnostics (CODX) announced its joint venture in India, CoSara Diagnostics, received clearance from the regulatory authorities to manufacture and sell SARAQ Hepatitis B ((HBV)) |
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load TestCo-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAQ™ Hepatitis B (HBV) Viral Load Kit as an in vitro diagnostic ("IVD"). |
Co-Diagnostics, Inc. to Host Booth at Medlab Middle East 2022 in Dubai on January 24-27Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Medlab Middle East 2022 trade show held January 24-27 at the Dubai World Trade Centre. |
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex TestCo-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAGENE™ Human Papillomavirus High-Risk (HPV-HR) Real-Time PCR test as an in vit |
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 BioConnect Virtual Conference on January 10-13Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be featured at the H.C. Wainwright & Co. 2022 BioConnect Conference, being held virtually on January 10-13. |
Co-Diagnostics, Inc. Announces Completion of the Acquisition of all Assets and Intellectual Property Related to At-Home/Point-of-Care PlatformCo-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the acquisition of Idaho Molecular Inc. and Advanced Conceptions, Inc. for nearly 4.72 million shares of the Company's stock, plus additional common warrants totaling 465,000, providing Co-Diagnostics with all existing and future assets and intellectual property related to the Company's upcom |